Persistent immune activation in chronic HIV infection: do any interventions work?

Reena Rajasuriar, Gabriela Khoury, Adeeba Binti Kamarulzaman, Martyn A French, Paul Urquhart Cameron, Sharon R Lewin

Research output: Contribution to journalArticleResearchpeer-review

54 Citations (Scopus)

Abstract

Persistent immune activation (IA) is a hallmark of chronic HIV infection. IA has been associated with poor CD4 T-cell recovery, non-AIDS defining illnesses and mortality during combination antiretroviral therapy (cART). Measures of chronic immune activation, namely T-cell activation and more recently monocyte activation and plasma inflammatory and thrombotic biomarkers, have all been shown to remain elevated despite years of suppressive cART. Here we review recent clinical trials and therapeutic approaches targeted to reduce persistent IA in HIV patients and discuss the impact of each of these approaches on clinically relevant end-points.
Original languageEnglish
Pages (from-to)1199 - 1208
Number of pages10
JournalAIDS
Volume27
Issue number8
DOIs
Publication statusPublished - 2013

Cite this

Rajasuriar, R., Khoury, G., Kamarulzaman, A. B., French, M. A., Cameron, P. U., & Lewin, S. R. (2013). Persistent immune activation in chronic HIV infection: do any interventions work? AIDS, 27(8), 1199 - 1208. https://doi.org/10.1097/QAD.0b013e32835ecb8b
Rajasuriar, Reena ; Khoury, Gabriela ; Kamarulzaman, Adeeba Binti ; French, Martyn A ; Cameron, Paul Urquhart ; Lewin, Sharon R. / Persistent immune activation in chronic HIV infection: do any interventions work?. In: AIDS. 2013 ; Vol. 27, No. 8. pp. 1199 - 1208.
@article{263c15fa31c44915bb1add7ce2731970,
title = "Persistent immune activation in chronic HIV infection: do any interventions work?",
abstract = "Persistent immune activation (IA) is a hallmark of chronic HIV infection. IA has been associated with poor CD4 T-cell recovery, non-AIDS defining illnesses and mortality during combination antiretroviral therapy (cART). Measures of chronic immune activation, namely T-cell activation and more recently monocyte activation and plasma inflammatory and thrombotic biomarkers, have all been shown to remain elevated despite years of suppressive cART. Here we review recent clinical trials and therapeutic approaches targeted to reduce persistent IA in HIV patients and discuss the impact of each of these approaches on clinically relevant end-points.",
author = "Reena Rajasuriar and Gabriela Khoury and Kamarulzaman, {Adeeba Binti} and French, {Martyn A} and Cameron, {Paul Urquhart} and Lewin, {Sharon R}",
year = "2013",
doi = "10.1097/QAD.0b013e32835ecb8b",
language = "English",
volume = "27",
pages = "1199 -- 1208",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams & Wilkins",
number = "8",

}

Rajasuriar, R, Khoury, G, Kamarulzaman, AB, French, MA, Cameron, PU & Lewin, SR 2013, 'Persistent immune activation in chronic HIV infection: do any interventions work?', AIDS, vol. 27, no. 8, pp. 1199 - 1208. https://doi.org/10.1097/QAD.0b013e32835ecb8b

Persistent immune activation in chronic HIV infection: do any interventions work? / Rajasuriar, Reena; Khoury, Gabriela; Kamarulzaman, Adeeba Binti; French, Martyn A; Cameron, Paul Urquhart; Lewin, Sharon R.

In: AIDS, Vol. 27, No. 8, 2013, p. 1199 - 1208.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Persistent immune activation in chronic HIV infection: do any interventions work?

AU - Rajasuriar, Reena

AU - Khoury, Gabriela

AU - Kamarulzaman, Adeeba Binti

AU - French, Martyn A

AU - Cameron, Paul Urquhart

AU - Lewin, Sharon R

PY - 2013

Y1 - 2013

N2 - Persistent immune activation (IA) is a hallmark of chronic HIV infection. IA has been associated with poor CD4 T-cell recovery, non-AIDS defining illnesses and mortality during combination antiretroviral therapy (cART). Measures of chronic immune activation, namely T-cell activation and more recently monocyte activation and plasma inflammatory and thrombotic biomarkers, have all been shown to remain elevated despite years of suppressive cART. Here we review recent clinical trials and therapeutic approaches targeted to reduce persistent IA in HIV patients and discuss the impact of each of these approaches on clinically relevant end-points.

AB - Persistent immune activation (IA) is a hallmark of chronic HIV infection. IA has been associated with poor CD4 T-cell recovery, non-AIDS defining illnesses and mortality during combination antiretroviral therapy (cART). Measures of chronic immune activation, namely T-cell activation and more recently monocyte activation and plasma inflammatory and thrombotic biomarkers, have all been shown to remain elevated despite years of suppressive cART. Here we review recent clinical trials and therapeutic approaches targeted to reduce persistent IA in HIV patients and discuss the impact of each of these approaches on clinically relevant end-points.

UR - http://www.natap.org/2013/HIV/Persistent_immune_activation_in_chronic_HIV.98703.pdf

U2 - 10.1097/QAD.0b013e32835ecb8b

DO - 10.1097/QAD.0b013e32835ecb8b

M3 - Article

VL - 27

SP - 1199

EP - 1208

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 8

ER -